Drug Profile
Anti-IL13 receptor alpha-2 chimeric antigen receptor T cell therapy - Juno Therapeutics
Alternative Names: Anti-interleukin13 receptor alpha-2 CAR-T cell therapy - Juno Therapeutics; CAR T cell therapy targeting IL13 receptor alpha-2 - Juno Therapeutics; IL13rα2 CAR-T cell therapy - Juno TherapeuticsLatest Information Update: 28 Apr 2021
Price :
$50
*
At a glance
- Originator Juno Therapeutics
- Class CAR-T cell therapies; Gene therapies; Immunotherapies
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Glioblastoma